Tumor necrosis-informed prognostic nomogram for clear cell renal cell carcinoma model development and clinical validation

基于肿瘤坏死信息的透明细胞肾细胞癌预后列线图模型开发及临床验证

阅读:1

Abstract

BACKGROUND: This study investigated the prognostic role of tumor necrosis (TN) in non-metastatic clear cell renal cell carcinoma (ccRCC). METHODS: We enrolled 1,212 non-metastatic ccRCC patients undergoing nephrectomy (2013-2023) in this retrospective study. Computer-generated randomization allocated cases to derivation (70%, n = 848) and validation cohorts (30%, n = 364). Kaplan-Meier methodology compared overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) across TN-positive and TN-negative cohorts, with intergroup differences evaluated by log-rank testing. Prognostic determinants were identified through univariate and multivariate Cox proportional hazards regression. We developed a prognostic nomogram through stepwise Cox regression that integrated TN status with key clinicopathological variables. Validation employed: Harrell's C-index, time-dependent ROC curves, calibration plots, and decision curve analysis (DCA). RESULTS: TN positivity was significantly associated with reduced OS (HR: 2.12, 95% CI: 1.65-2.73; P < 0.001), CSS (HR: 2.45, 95% CI: 1.82-3.29; P < 0.001), and RFS (HR: 1.89, 95% CI: 1.32-2.70; P = 0.003) in multivariate analysis. The prognostic nomogram demonstrated excellent discrimination in the validation cohort, with C-indices of 0.855 (OS), 0.870 (CSS), and 0.724 (RFS). Time-dependent ROC analysis revealed robust predictive accuracy for OS at 1- (AUC: 0.892), 3- (AUC: 0.846), and 5-year (AUC: 0.826) intervals. Calibration curves demonstrated excellent consistency between predicted probabilities and actual outcomes. Decision curve analysis further revealed greater clinical net benefit than pT stage system and WHO/ISUP classification. CONCLUSION: TN is an independent prognostic marker in non-metastatic ccRCC. The novel nomogram integrating TN provides reliable risk stratification, aiding personalized postoperative management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。